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Background/aim: Atherosclerotic heart diseases can occur at an early age in patients with ankylosing spondylitis (AS). Flow-mediated
dilation (FMD) and carotid intima-media thickness (cIMT) values are reliable markers for early detection of subclinical atherosclerosis
in patients with AS. We aimed to investigate the relationship between visfatin levels and indirect markers of subclinical atherosclerosis
and endothelial dysfunction in patients with AS.
Materials and methods: Forty-two patients diagnosed with AS and 42 age, sex, and body mass index (BMI)-matched controls were
included in the study. Visfatin levels, FMD, and cIMT were measured using appropriate methods.
Results: Visfatin levels of the patients were significantly higher than controls (p < 0.001). FMD values in patients with AS were
significantly lower (p = 0.007) whereas cIMT were significantly higher than the controls (p = 0.003). There was a negative relationship
between FMD with visfatin levels (p = 0.004), BASDAI (p = 0.010), and BASFI (p = 0.007). There was a positive relationship between
cIMT with visfatin (p = 0.005), BASDAI (p < 0.001), and BASFI (p < 0.001). There was a positive relationship between visfatin with
BASDAI (p < 0.001), and BASFI (p < 0.001).
Conclusion: Visfatin levels are increased and associated with impaired FMD and increased cIMT in patients with AS. Increased visfatin
levels may be associated with subclinical atherosclerosis in AS.
Key words: Visfatin, ankylosing spondylitis, flow-mediated dilation, carotid intima-media thickness, subclinical atherosclerosis

1. Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease-causing destruction in the spinal and peripheral
joints [1]. Multilevel organ and system involvement
including eye, skin, kidney, gastrointestinal, and
cardiovascular systems may occur in the course of AS.
Cardiovascular system involvement is seen in 2% to 10%
of patients with AS and cardiovascular risk is increased
compared to the healthy population [2–4]. Cardiac
involvement may occur in various forms ranging from
asymptomatic atherosclerosis to mortal conduction
disorders, ischemic heart disease, aortic valve diseases,
aortitis, hypertension, and cardiomyopathy [5]. Findings
of atherosclerosis may be detected even at an early stage

of the disease, and chronic inflammation is considered as
an important contributing factor in the development of
atherosclerosis in AS [6].
The carotid intima-media thickness (cIMT)
measurement is suggested as a cost-effective, reliable,
and noninvasive method for detecting subclinical
atherosclerosis in patients with AS [7]. Flow-mediated
dilatation (FMD) is another noninvasive method for
early detection of endothelial dysfunction which reflects
the dilation rate of an artery due to nitric oxide released
from endothelial cells [8]. FMD can detect endothelial
dysfunction caused by decreased bioavailability of nitric
oxide released from the endothelium [9]. Impaired FMD
can be detected before apparent atherosclerotic changes
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may occur and is an early and reliable marker of endothelial
damage [10].
Visfatin
also
called
nicotinamide
phosphoribosyltransferase (NAMPT) and pre-B cell
colony enhancing factor (PBEF), was first described in 2004
[11]. Visfatin is an adipokine predominantly released from
visceral adipose tissue but also released from all tissues
[12]. Visfatin is a pro-inflammatory cytokine and also
increases the release of other pro-inflammatory cytokines
such as interleukin (IL) -1beta, IL-6, and tumor necrosis
factor-alpha from monocytes and vascular endothelial cells
and results in severe inflammation [13]. Increased visfatin
levels are associated with vascular inflammation and
carotid plaques [14]. Increased circulatory visfatin levels
have been reported in various inflammatory diseases such
as rheumatoid arthritis, inflammatory bowel diseases, and
psoriasis [12]. Elevated visfatin levels has been reported
as a predictor of radiographic progression in patients with
AS [15,16]. Visfatin levels were associated with increased
cIMT values and impaired FMD [17,18].
In this study, we aimed to investigate the possible
relationship between endothelial dysfunction and visfatin
levels in patients with AS.
2. Materials and methods
2.1. Patients
Forty-two patients with AS who met the modified New
York criteria and 42 age-, sex-, and body mass index
(BMI)-matched healthy controls were included in the
study. Patients were consequently recruited from Malatya
State Hospital rheumatology and physical medicine and
rehabilitation outpatient clinics. Individuals who were
pregnant or nursing women, or had diagnosis for malign
tumors, diabetes mellitus, hypertension, heart disease,
hyperlipidemia, acute or chronic infections, acute or
chronic renal failure, chronic obstructive pulmonary
disease, and obesity (BMI ≥ 30 kg/m2) were excluded.
2.1.1. Sample size
The prevalence of AS is 0.5%–1.4%. The incidence
of atherosclerosis in the community is 27.6% [19].
Atherosclerosis is seen 1.4–1.7-fold more in AS patients
than in the population [20]. The minimum sample size
required to find statistical significance was calculated with
the Sample Size Calculator1, considering 0.05 type I error
(alpha), 0.8 power (1-beta), effect size 0.68, and the twosided alternative hypothesis (H1). The minimum number
of patients and controls to be included in the study was
calculated as 36 each.
2.1.2. Current smoker
Current smokers were recorded according to the definition
of the National Health Interview Survey “Current
1

Sample Size Calculator [clincalc.com]).

2

https://www.smokingpackyears.com/.
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smoker: An adult who has smoked 100 cigarettes in his
or her lifetime and who currently smokes cigarettes.” The
smoking duration was calculated as packs-year2.
2.2. Biochemical analysis
Venous blood samples of the patients and controls were
collected after 12 h of fasting. Blood samples were taken
into dry tubes, divided and separated into small pieces,
and stored at –80 °C until analyzed. Complete blood count
analysis was performed by flow cytometry device (Mindray
BC-6800 Auto Hematology Analyzer, Shenzhen, China).
C-reactive protein (CRP), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), blood urea
nitrogen (BUN) creatinine values were measured using a
spectrophotometry device (Abbot-Architect c8000, Japan).
The erythrocyte sedimentation rate (ESR) was evaluated
by the Westergren method (Berkhun SDM-100, Turkey).
2.3. Visfatin measurement
Serum blood samples for visfatin were taken from
all patients and controls between 08.00–09.00 in the
morning after 12 h of fasting. Visfatin measurement of all
individuals was made from their serum samples on the
same day. Serum visfatin level was measured by enzymelinked immunosorbent method (ELISA) using the Elisa
kit (Elabscience, China). The process was carried out
following the manufacturer’s instructions. Absorbance
was evaluated at 450 nm by an ELISA reader.
2.4. Ultrasonography
Ultrasonographic (US) measurements were made by the
same experienced radiologist using a high-resolution
ultrasound device (Logiq S6; General Electric, Milwaukee,
WI, USA) and a 12 MHz multi-frequency linear probe.
Sonography was performed by the patient in the supine
position and the neck turned to the side of examination.
US evaluations in patients and controls were performed in
the morning (9:00–10:00 AM) after 12 h of fasting. Twelve
hours before the study, all subjects were discontinued
smoking, alcohol, and caffeine consumption, and exercise
are not permitted.
2.5. Measurement of carotid intima-media thickness
Intima-media thickness (IMT) measurements were
attained from nonplaque areas of the three different points
of the right and left common carotid artery (CCA) and
1 cm distant from the bifurcation. Two bright echogenic
lines on the arterial wall were identified as intima and
media. A total of three measurements were made for each
side of the body, the average of three measurements was
calculated as the IMT value.
2.6. Method of evaluating flow-mediated dilation
The participants were placed in the supine position
and rested for at least 10 min. Then, the brachial blood
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pressure was measured and noted. Subsequently, FMD
was measured using an echography (Vivid S6, GE, USA)
equipped with a linear probe (frequency range, 12 MHz).
The basal measurement of the right brachial artery
diameter was performed in a linear plane and nearly 2 to 3
cm upper from the antecubital fossa. Afterward, a cuff was
placed around the forearm distal to the ultrasonographic
evaluation line. The cuff was inflated to supra systolic
pressure (50 mm Hg above the previously measured
systolic blood pressure) and held in this position for 5
min of ischemia. The diameter of the brachial artery was
re-measured 1 min after the cuff was completely deflated.
FMD value was obtained by calculating the percentage
increase in diameter of the brachial artery.
2.7. Statistical analysis
SPSS program (version 20) was used for the evaluation of
all statistical analyzes in the study. Kolmogorov–Smirnov
test was used to show the homogeneity of distribution. The
t-test or Mann–Whitney U test was used for comparison
between groups and Pearson correlation coefficients or
Spearman rank test for analyzing relationship between
parameters where appropriate. The categorical variables
such as age and current smoking were evaluated using the
chi-square test. Independent variables affecting cIMT and
FMD were determined using linear stepwise regression
analysis. Before performing stepwise linear regression
analysis, univariate analysis was performed to determine
independent variables associated with cIMT and FMD. In
univariate analysis, for cIMT, age, male sex, visfatin, Bath
ankylosing spondylitis disease activity index (BASDAI),
Bath ankylosing spondylitis functional index (BASFI),
fasting plasma glucose (FPG), total cholesterol (TC), lowdensity cholesterol (LDL), triglyceride (TG), CRP, and
ESR were determined as independent variables. For FMD,
BASDAI, BASFI, disease duration, creatinine, TC, and
LDL were determined as independent variables. A p-value
of < 0.05 was considered statistically significant.
3. Results
Age, sex, and BMI values of the patients and controls were
similar (p > 0.05). Alcohol and tobacco consumptions
were similar between groups. The regions where we detect
enthesitis in patients are: costochondral joints (n = 4),
trochanter major (n = 3), anterior superior iliac spine (n
= 3), iliac crest (n = 1), posterior superior iliac spine (n =
1), processus spinosus (n = 6), achilles tendon region (n =
4), and multiple sites (n = 2). The median disease duration
of patients with AS was 3.5 years. Sociodemographic
characteristics of the patients and healthy controls are
shown in Table 1.
Visfatin levels of the patients were significantly higher
than healthy controls (p < 0.001) (Table 2). FMD values
of the patients were lower than controls (p = 0.007),

Table 1. Sociodemographic characteristics of the patient and
control groups.
AS
(n = 42)

Control
(n = 42)

Age (years)

39.2 ± 7.3

39.4 ± 9.6 0.929

Sex (M/F) (n)

13/29

13/29

Disease duration (years)

3.5 (1.0–45.0)

P value

1.000

Peripheral arthritis n, (%) 2 (4.8)
Enthesitis n, (%)

24 (57.1)

BASDAI

3.2 ± 1.3

BASFI

2.8 ± 1.3

BMI (kg/m )

26.8 ± 3.6

25.9 ± 5.0 0.361

Current smokers (n)

13

16

Smoking (packet-years)

18.5 ± 4.3

14.6 ± 8.0 0.108

Drinking (n)

1

0

NSAID (n)

21

MTX (n)

14

Infliximab (n)

5

Adalimumab (n)

4

Etanercept (n)

6

Certolizumab (n)

4

Salazopyrin (n)

2

Topical steroid

1

Systemic steroid

0

2

0.412
1.000

Abbreviations: AS, ankylosing spondylitis; BASDAI, bath
ankylosing spondylitis disease activity index; BASFI, bath
ankylosing spondylitis functional index; BMI, body mass
index; NSAID, nonsteroidal antiinflammatory drug; MTX,
methotrexate.

whereas their cIMT values were higher than the controls
(p = 0.003). Serum uric acid, CRP and ESR values of the
patients were higher than the controls (Table 2). Highdensity lipoprotein (HDL) values of the patients were lower
than healthy controls. Visfatin, FMD, and cIMT values of
the patients and controls are shown in Figures 1, 2, and
3, respectively. All biochemical results of the patients are
shown in Table 2.
There was a negative correlation between FMD values
with visfatin (p = 0.004), BASDAI (p = 0.010), and BASFI
(p = 0.007). There was positive relationship between
cIMT with visfatin (p = 0.005), BASDAI (p < 0.001),
and BASFI (p < 0.001). There was a negative relationship
between cIMT and HDL. There was a positive relationship
between visfatin with BASDAI (p < 0.001), and BASFI
(p < 0.001). There was a negative relationship between
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Table 2. Biochemical results of the patient and control group.
AS (n = 42)

Control (n = 42)

P value

Visfatin (ng/mL)

3.5 (0.19–19.3)

1.3 (0.17–7.0)

<0.001

FMD (%)

7.2 ± 2.8

8.7 ± 1.7

0.007

cIMT mm

0.50 ± 0.1

0.44 ± 0.1

0.003

Carotid plaque (n)

0

0

1.000

FPG (mg/dL)

99.6 ± 22.3

93.4 ± 16.1

0.144

BUN (mg/dL)

25.8 ± 7.5

29.9 ± 8.2

0.020

Creatinine (mg/dL)

0.7 ± 0.08

0.7 ± 0.18

0.106

AST (IU/L)

22.0 ± 11.9

22.8 ± 10.2

0.733

ALT (IU/L)

27.4 ± 18.7

24.8 ± 16.3

0.502

SUA (mg/dL)

4.3 ± 0.9

3.3 ± 0.6

<0.001

CRP (mg/dL)

0.20 (0.10–4.82)

0.10 (0.10–2.15)

0.008

ESR (mm/h)

23.2 ± 17.5

14.7 ± 11.3

0.007

WBC (×10 /L)

7.5 ± 2.0

7.2 ± 1.4

0.463

Hb (g/dL)

13.5 ± 1.9

13.3 ± 1.3

0.668

TSH (mIU/L)

1.7 ± 0.9

1.8 ± 1.1

0.788

TC (mg/dL)

191.3 ± 39.7

199.8 ± 25.2

0.250

TG (mg/dL)

131.9 ± 52.5

128.8 ± 53.7

0.792

HDL (mg/dL)

40.2 ± 8.6

48.3 ± 9.8

<0.001

LDL (mg/dL)

124.7 ± 35.6

125.7 ± 19.8

0.883

9

Abbreviations: AS, ankylosing spondylitis; FMD, flow-mediated dilation; cIMT, carotid intimamedia thickness; FPG, fasting plasma glucose; BUN, blood urea nitrogen; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; SUA, serum uric acid; CRP, C-reactive
protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; Hb, hemoglobin;
TSH, thyroid stimulating hormone; TC, total cholesterol; TG, triglyceride; HDL, high-density
lipoprotein; LDL, low-density lipoprotein.

visfatin and HDL. All results of correlation analysis are
shown in Table 3.
Stepwise linear regression analysis was performed
after finding independent variables related to cIMT and
FMD according to univariate analysis. In the stepwise
linear regression analysis (r2 = 0.551, F = 24.2, p < 0.001
for cIMT; r2 = 0.251, F: 6.6, p < 0.001 for FMD); there was
an independent inverse relationship between FMD with
visfatin (beta [β] = 0.223, p = 0.045), and BASFI (β = 0.290,
p = 0.011). There was an independent association between
cIMT with age (β = 0.431, p < 0.001), BASFI (β = 0.371, p
< 0.001), and male sex (β = 0.298, p < 0.001). All results
of univariate and stepwise linear regression analysis are
shown in Table 4 and Table 5.
4. Discussion
Our results revealed that cIMT, a marker of subclinical
atherosclerosis, was higher in patients with AS than
matched healthy controls, and FMD, a marker of
endothelial dysfunction, is lower in patients than controls,
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indication poorer endothelial functions. Our results also
showed that serum levels of visfatin were higher in patients
with AS compared to controls, and higher levels of visfatin
may be associated with higher disease activity and poorer
physical functions.
The increased risk of atherosclerosis is known in
patients with AS. Chronic inflammation which disrupts
endothelial functions and steroid and nonsteroid
antiinflammatory drugs used in the treatment are factors
contributing to the increased cardiovascular risk in
patients with AS [3,21,22].
Visfatin is a multiple immunomodulatory protein that
stimulates the release of pro-inflammatory cytokines.
Visfatin activates leukocytes and causes pro-inflammatory
cytokine release, resulting in an increase in inflammation
and reactive oxygen species [23]. Increased visfatin
levels were shown associated with insulin resistance and
increased cardiac events [24]. An independent relationship
was found between visfatin levels with coronary artery
disease and coronary slow-flow phenomenon [25]. Zheng
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Figure 1. Serum visfatin levels of AS patients were higher than the control group.
AS: ankylosing spondylitis.

Figure 2. FMD values of the patients with AS were lower than the healthy control
group. FMD: flow-mediated dilatation; AS: ankylosing spondylitis.

Figure 3. Patients with AS had higher cIMT values than healthy controls. cIMT:
carotid intima-media thickness; AS: ankylosing spondylitis.
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Table 3. Correlation analysis results of patients.
Parameters

FMD

cIMT

Visfatin

R value

P value

R value

P value

R value

P value

Visfatin

–0310

0.004

0.301

0.005

BASDAI

–0.281

0.010

0.396

BASFI

–0.294

0.007

0.427

<0.001

0.479

<0.001

<0.001

0.441

<0.001

SUA

–0.280

0.010

Age

0.506

<0.001

0.257

0.018

FPG

0.219

0.045

CRP

0.314

0.004

ESR

0.229

0.036

0.236

0.030

0.342

0.001

0.368

<0.001

HDL

–0.218

0.036

LDL

0.322

0.003

–0.229

0.036

TG

0.407

<0.001

Disease duration
TC

–0.222

0.041

Abbreviations: FMD, flow-mediated dilation; cIMT, carotid intima-media thickness; BASDAI,
bath ankylosing spondylitis disease activity index; BASFI, bath ankylosing spondylitis
functional index; SUA, serum uric acid; FPG, fasting plasma glucose; CRP, C-reactive protein;
ESR, erythrocyte sedimentation rate; TC, total cholesterol; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; TG, triglyceride.

et al. found a strong relationship between increased
visfatin levels (>8.799 ng/mL) and major adverse
cardiovascular events (MACEs) in acute myocardial
infarction [26]. Stejskal et al. reported that the 20 ng/
mL cut-off value of visfatin is an independent marker for
AMI with high sensitivity (84%) and specificity (90%)
[27]. Miranda–Filloy et al. found visfatin levels higher
in AS patients than healthy controls, but they did not
find any relationship between visfatin level with lipid
parameters and BASDAI [28]. Hulejova et al. found a
positive relationship between visfatin and BASDAI in
patients with axial spondyloarthritis [28]. In the current
study, we found a relationship between serum visfatin
levels with both BASDAI and BASFI. We found a
negative relationship between visfatin with HDL, which
has a potent antiatherosclerotic effect.
Atherosclerosis and cardiac events can be seen at an
early age in AS [29]. Impaired FMD is a good marker
of subclinical atherosclerosis. Bodnar et al. found that
FMD values are significantly lower and cIMT values
remarkably higher in patients with AS compared to
controls [30]. Wang et al. found that in 120 AS patients,
the FMD value was pronouncedly lower than the control
group [31]. There is an inverse relationship between the
circulating visfatin levels with FMD, an early marker
of endothelial dysfunction [32]. Yilmaz et al. showed
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a relationship between endothelial dysfunction and
visfatin in 406 patients with chronic renal failure [33].
The cIMT value has been proven to be a reliable marker
for early detection of subclinical atherosclerosis in patients
with AS [7,34]. A positive correlation was shown between
serum visfatin levels and cIMT in diabetic and nondiabetic
hemodialysis patients [35]. Zhong et al. reported that the
relationship between serum visfatin levels and carotid
plaque, and an increase in visfatin levels was a predictive
marker for the carotid plaque with 70% sensitivity and
67% specificity [36].
Regarding rheumatic diseases which progress with
aberrant inflammation, higher visfatin levels with respect
to controls and high disease activity compatible with
visfatin levels were shown in patients with rheumatoid
arthritis and Behçet’s disease but no relationship between
cIMT and glucose intolerance [37]. On the other hand,
contradictory results were reported in patients with
systemic lupus erythematosus and systemic sclerosis
indicating similar levels of visfatin compared with controls
[35]. Syrbe et al. reported higher serum visfatin levels in
patients with AS [15].
To the best of our knowledge, our study is the first
to investigate cIMT and FMD together and possible
interactions between circulating visfatin levels and disease
parameters in patients with AS.
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Table 4. Independent variables associated with cIMT and FMF in univariate
analysis.
cIMT

FMD

Beta

P value

Beta

P value

Age

0.506

<0.001

0.028

0.799

Male sex

0.255

0.019

0.140

0.203

Visfatin

0.301

0.005

0.310

0.004

BMI

0.111

0.314

0.021

0.847

BASDAI

0.396

<0.001

0.281

0.010

BASFI

0.427

<0.001

0.294

0.007

FPG

0.219

0.045

0.041

0.713

BUN

0.069

0.533

0.013

0.909

Creatinine

0.020

0.854

0.281

0.010

TC

0.342

0.001

0.222

0.042

HDL

0.212

0.053

0.107

0.302

LDL

0.322

0.003

0.280

0.010

TG

0.407

<0.001

0.060

0.585

SUA

0.104

0.344

0.198

0.070

CRP

0.314

0.004

0.007

0.949

ESR

0.229

0.036

0.082

0.457

AST

0.101

0.359

0.139

0.208

ALT

0.184

0.094

0.184

0.094

WBC

0.022

0.845

0.132

0.232

Hb

0.054

0.623

0.014

0.896

TSH

0.040

0.715

0.062

0.574

Smoking

0.096

0.546

0.250

0.111

Disease duration

0.245

0.117

0.346

0.025

Abbreviations: cIMT, carotid intima-media thickness; FMD, flow-mediated
dilation; BMI, body mass index; BASDAI, bath ankylosing spondylitis disease
activity index; BASFI, bath ankylosing spondylitis functional index; FPG,
fasting plasma glucose; BUN, blood urea nitrogen; TC, total cholesterol; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; SUA,
serum uric acid; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white
blood cell count; Hb, hemoglobin; TSH, thyroid stimulating hormone.

Possible interactions between visfatin and FMD with
uric acid levels and estimated glomerular filtration rate
(eGFR) has been described in different disease groups
[38,39]. In our study, we found a relationship between
visfatin and FMD and serum creatinine. Low-density
lipoprotein (LDL) is a highly proatherogenic molecule and
Matsui et al., revealed a strong relationship between LDL
and impaired FMD in statin naive individuals [40]. In our
study, we also found a relationship between LDL and FMD.

5. Limitation of the study
Our study has some limitations. The study was conducted
with a small number of subjects. Current study is a pilot
study and studies with broad participation are needed.
Another missing point in our study is the absence of the
diseased-control group. The number of patients with
high disease activity (BASDAI> 4) was quite low. The
relationship between visfatin and cIMT and FMD in AS
patients should be investigated in further studies.
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Table 5. Stepwise linear regression analysis.
Dependent variable

Independent variables

Beta regression coefficient

P value

FMD

Visfatin

–0.223

0.045

Creatinine

–0.263

0.010

BASFI

–0.290

0.011

LDL

–0.219

0.031

Age

0.431

<0.001

BASFI

0.371

<0.001

Male sex

0.298

<0.001

TG

0.242

0.003

cIMT

Abbreviations: FMD, flow-mediated dilation; cIMT, carotid intima-media thickness; BASFI, bath
ankylosing spondylitis functional index; LDL, low-density lipoprotein; TG, triglyceride.

6. Conclusion
Circulating visfatin levels are associated with disease
activity and functional ability in patients with AS, and along
with cIMT and FMD may be associated with increased risk
of subclinical atherosclerosis and endothelial dysfunction.
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